Rockefeller Capital Management’s Cardiff Oncology CRDF Stock Holding History

Rockefeller Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$30.2K	Buy	25,000 +5,000	+25%	+$5.36K	﹤0.01%	3709
2026 Q2	$26K	Sell	20,000 -36,500	-65%	-$58K	﹤0.01%	3648
2026 Q1	$91.5K	Hold	56,500	–	–	﹤0.01%	2929
2025 Q4	$159K	Sell	56,500 -6,000	-10%	-$13.9K	﹤0.01%	2485
2025 Q3	$129K	Buy	+62,500	New	+$173K	﹤0.01%	2445
2022 Q4	–	Sell	-163	Closed	–	–	3894
2022 Q3	$0	Hold	163	–	–	﹤0.01%	3949
2022 Q2	$0	Buy	163 +156	+2,229%	+$261	﹤0.01%	4140
2022 Q1	$0	Buy	7 +1	+17%	+$4	﹤0.01%	3893
2021 Q4	$0	Buy	+6	New	+$36	﹤0.01%	3799
2021 Q3	–	Sell	-882	Closed	-$5K	–	3709
2021 Q2	$5K	Sell	882 -353	-29%	-$2.99K	﹤0.01%	3022
2021 Q1	$11K	Buy	1,235 +1,061	+610%	+$12.9K	﹤0.01%	2535
2020 Q4	$3K	Sell	174 -6,880	-98%	-$121K	﹤0.01%	2546
2020 Q3	$100K	Buy	+7,054	New	+$46.6K	﹤0.01%	1253

Other funds holding CRDF

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Pfizer New York $164M AUM 53.62% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Rockefeller Capital Management's CRDF Position: Q3 2026 in Review

Rockefeller Capital Management increased its Cardiff Oncology (CRDF) stake by 25% in Q3 2026, buying an estimated $5.36K and bringing the position to 25,000 shares worth $30.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3709.

Rockefeller Capital Management first reported a position in CRDF in Q3 2020 and has held it in 13 quarters since. The position peaked at $159K in Q4 2025. 63 funds tracked by Wall St. Rank hold CRDF as of Q3 2026.

Rockefeller Capital Management held 25,000 shares of Cardiff Oncology worth $30.2K as of Q3 2026.
Rockefeller Capital Management bought 5,000 Cardiff Oncology shares in Q3 2026, an estimated $5.36K.
Cardiff Oncology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3709 holding.
Rockefeller Capital Management first reported a position in Cardiff Oncology in Q3 2020 and has held it in 13 quarters since.
Rockefeller Capital Management's Cardiff Oncology position peaked at $159K in Q4 2025.
63 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.